Present management of gastrointestinal stromal tumors

Czech version

Authors: S. Batko
Authors‘ workplace: Onkologická klinika 2. LF UK a FN Motol
Published in: Klin Onkol 2025; 38(3): 170-176
Category: Reviews
doi: https://doi.org/10.48095/ccko2025170

Overview

Background: Gastrointestinal stromal tumors (GISTs) are rare tumors of the digestive tract that have seen significant advances in diagnosis and treatment in recent years. A key breakthrough was the identification of c-KIT and PDGFRA gene mutations, which enabled the introduction of targeted therapies. The cornerstone of the treatment for localized disease is radical (R0) surgical resection, with adjuvant imatinib recommended for patients at high risk of recurrence. In advanced or metastatic disease, standard care involves sequential treatment with tyrosine kinase inhibitors, including imatinib, sunitinib, and regorafenib. A major advance is represented by ripretinib, which effectively inhibits a broad spectrum of KIT and PDGFRA mutations and has been shown to prolong survival in patients with advanced GIST refractory to current options of systemic therapy. The expanding range of targeted therapies, such as avapritinib for the PDGFRA D842V mutation, underscores the importance of molecular profiling in guiding optimal treatment strategies. Aim: This review aims to summarize current knowledge on the diagnosis and treatment of GIST, with a focus on the role of molecular-genetic profiling, the therapeutic value of individual tyrosine kinase inhibitors, and emerging options for advanced disease, with particular emphasis on ripretinib.

Keywords:

GIST – sunitinib – imatinib – regorafenib – systemic treatment – ripretinib – avapritinib

Sources

1. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7 (6): 507–519. doi: 10.1097/00000478-198309000-00001.

2. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279 (5350): 577–580. doi: 10.1126/science.279.5350.577.

3. Khan J, Ullah A, Waheed A et al. Gastrointestinal Stromal Tumors (GIST): a population-based study using the SEER database, including management and recent advances in targeted therapy. Cancers (Basel) 2022; 14 (15): 3689. doi: 10.3390/cancers14153689.

4. Søreide K, Sandvik OM, Søreide JA et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol 2016; 40: 39–46. doi: 10.1016/j.canep.2015.10.031.

5. Jurečková A, Kocáková I, Vyzula R. GIST registry. Klin Onkol 2012; 25 (2): 135–138.

6. Feng F, Feng B, Liu S et al. Clinicopathological features and prognosis of mesenteric gastrointestinal stromal tumor: evaluation of a pooled case series. Oncotarget 2017; 8 (28): 46514–46522. doi: 10.18632/oncotarget.14880.

7. Kawanowa K, Sakuma Y, Sakurai S et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37 (12): 1527–1535. doi: 10.1016/j.humpath.2006.07.002.

8. Daumová M, Vaňková B, Švajdler M et al. Immunohistochemistry and molecular genetics in the differential diagnostics of mesenchymal lesions of gastrointestinal tract. Cesk Patol 2020; 56 (4): 212–220.

9. Liegl B, Hornick JL, Corless CL et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009; 33 (3): 437–446. doi: 10.1097/pas.0b013e318186b158.

10. Kelly CM, Sainz LG, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol 2021; 14 (1): 2. doi: 10.1186/s13045-020-01026-6.

11. Kalfusova A, Linke Z, Kalinova M et al. Gastrointestinal stromal tumors – summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects. Pathol Res Pract 2019; 215 (12): 152708. doi: 10.1016/j.prp.2019.152708.

12. Gopie P, Mei L, Faber AC et al. Classification of gastrointestinal stromal tumor syndromes. Endocr Relat Cancer 2018; 25 (2): R49–R58. doi: 10.1530/ERC-17-0329.

13. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33 (5): 459–465. doi: 10.1053/hupa. 2002.123545.

14. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with longterm follow-up and review of the literature. Am J Surg Pathol 2005; 29 (10): 1373–1381. doi: 10.1097/01.pas.0000172190.79552.8b.

15. Joensuu H, Eriksson M, Hall KS et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer 2014; 120 (15): 2325–2333. doi: 10.1002/cncr.28669.

16. Joensuu H, Vehtari A, Riihimäki J et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13 (3): 265–274. doi: 10.1016/S1470-2045 (11) 70299-6.

17. Rahimi-Ardabily A, Murdande S, Dong M et al. Liver resection for metastatic GIST tumor improves survival in the era of tyrosine kinase inhibitors: a systematic review and meta-analysis. Langenbecks Arch Surg 2023; 408 (1): 373. doi: 10.1007/s00423-023-03052-7.

18. Avritscher R, Gupta S. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematol Oncol Clin North Am 2009; 23 (1): 129–137. doi: 10.1016/j.hoc.2008.11.002.

19. Joensuu H, Eriksson M, Collan J et al. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: a prospective study. Radiother Oncol 2015; 116 (2): 233–238. doi: 10.1016/j.radonc.2015.07.025.

20. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472–480. doi: 10.1056/NEJMoa020461.

21. Blanke CD, Demetri GD, von Mehren M et al. Long--term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26 (4): 620–625. doi: 10.1200/JCO.2007.13.4403.

22. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26 (4): 626–632. doi: 10.1200/JCO.2007.13.4452.

23. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high- -dose imatinib: randomised trial. Lancet 2004; 364 (9440): 1127–1134. doi: 10.1016/S0140-6736 (04) 17098-0.

24. Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41 (12): 1751–1757. doi: 10.1016/j.ejca.2005.04.034.

25. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42 (8): 1093–1103. doi: 10.1016/j.ejca.2006. 01.030.

26. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group. J Clin Oncol 2008; 26 (33): 5360–5367. doi: 10.1200/JCO.2008.17.4284.

27. Heinrich MC, Rankin C, Blanke CD et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol 2017; 3 (7): 944–952. doi: 10.1001/jamaoncol.2016.6728.

28. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373 (9669): 1097–1104. doi: 10.1016/S0140-6736 (09) 60500-6.

29. Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307 (12): 1265–1272. doi: 10.1001/jama.2012.347.

30. Blay JY, Schiffler C, Bouché O et al. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Ann Oncol 2024; 35 (12): 1157–1168. doi: 10.1016/j.annonc.2024.08.2343.

31. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368 (9544): 1329–1338. doi: 10.1016/S0140-6736 (06) 69446-4.

32. Demetri GD, Garrett CR, Schöffski P et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012; 18 (11): 3170–3179. doi: 10.1158/1078-0432.CCR-11-3005.

33. George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45 (11): 1959–1968. doi: 10.1016/j.ejca.2009.02.011.

34. Rutkowski P, Bylina E, Klimczak A et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure – one institution study. BMC Cancer 2012; 12: 107. doi: 10.1186/1471-2407-12-107.

35. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381 (9863): 295–302. doi: 10.1016/S0140-6736 (12) 61857-1.

36. Demetri G, Reichardt P, Kang YK et al. An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID). J Clin Oncol 2015; 26 (Suppl 6): vi96. doi: 10.1093/annonc/mdv344.21.

37. Smith BD, Kaufman MD, Lu WP et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 2019; 35 (5): 738–751.e739. doi: 10.1016/j.ccell.2019.04.006.

38. Blay JY, Serrano C, Heinrich MC et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21 (7): 923–934. doi: 10.1016/S1470-2045 (20) 30168-6.

39. von Mehren M, Heinrich MC, George S et al. Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: long-term update from the phase III INVICTUS study. Ann Oncol 2021; 32 (Suppl 5): S1111–S1128. doi: 10.1016/j.annonc.2021.08.870.

40. Zalcberg JR, Heinrich MC, George S et al. Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study. Oncologist 2021; 26 (11): e2053–e2060. doi: 10.1002/onco.13917.

41. Jones RL, Serrano C, von Mehren M et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 2021; 145: 132–142. doi: 10.1016/j.ejca.2020.12.008.

42. Casali PG, Blay JY, Abecassis N et al. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2022; 33 (1): 20–33. doi: 10.1016/j.annonc.2021.09.005.

43. NCCN Guidelines. Gastrointestinal tumors. [online]. Available from: https: //www.nccn.org/guidelines/guidelines-detail?category=1&id=1507